IP Library Granted Patent US 9,623,087
Granted Patent B2
US 9,623,087 · App. 14/361,787 · Granted Apr 18, 2017

Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,623,087
App. No.
14/361,787
Granted
Apr 18, 2017
Kind
B2
Abstract

A medical device including an array of microneedles and a coating disposed on or within the microneedles and a method of making such a device are disclosed. The coating includes a peptide therapeutic agent and an amino acid. A method of stabilizing a peptide therapeutic agent with an amino acid on an array of microneedles is also disclosed. In some cases, the peptide therapeutic agent and the amino acid either both have a net positive charge or both have a net negative charge. In some cases, the peptide therapeutic agent is histidine.

Claims (27)

1. A medical device comprising:

an array of microneedles; and

a coating on or within at least a portion of the microneedles, wherein the coating comprises:

a peptide therapeutic agent; and

an amino acid,

wherein the peptide therapeutic agent and the amino acid both have a net positive charge, and

wherein the peptide therapeutic agent is a parathyroid hormone-related protein analogue represented by formula [Glu 22,25 , Leu 23,28,31 , Aib 29 , Lys 26,30 ]hPTHrP(1-34)NH 2 .

2. The medical device of claim 1 , wherein the coating is substantially free of sorbitol.

3. The medical device of claim 1 , wherein the amino acid is histidine.

4. The medical device of claim 3 , wherein the molar ratio of the histidine to the peptide therapeutic agent is less than 2:1.

5. The medical device of claim 4 , wherein the molar ratio of the histidine to the peptide therapeutic agent is less than 1.5:1.

6. The medical device of claim 3 , wherein the histidine stabilizes the peptide therapeutic agent in the coating.

7. The medical device of claim 1 , wherein the molar ratio of the amino acid to the peptide therapeutic agent is less than 2:1.

8. The medical device of claim 7 , wherein the molar ratio of the amino acid to the peptide therapeutic agent is in a range from 0.5:1 to 55:1.

9. The medical device of claim 1 , wherein the amino acid is histidine, arginine, or lysine.

10. The medical device of claim 1 , wherein the amino acid is present in the coating in a range from 0.1 to 15 percent by weight, based on the total weight of the coating.

11. The medical device of claim 1 , wherein the array of microneedles comprises a dissolvable matrix material, or wherein at least some of the microneedles are hollow.

12. A method of making a medical device comprising microneedles, the method comprising:

providing an aqueous composition comprising a peptide therapeutic agent, an amino acid, and a buffer, wherein the peptide therapeutic agent and the amino acid both have a net positive charge in the aqueous composition;

contacting the microneedles with the aqueous composition; and

volatilizing a portion of the aqueous composition to provide a coating on at least a portion of the microneedles, wherein the coating comprises at least the peptide therapeutic agent and the amino acid, and wherein the peptide therapeutic agent is a parathyroid hormone-related protein analogue represented by formula [Glu 22,25 , Leu 23,28,31 , Aib 29 , Lys 26,30 ]hPTHrP(1-34)NH 2 .

13. The method of claim 12 , wherein the aqueous composition has a pH in a range from 3 to 11.

14. The method of claim 12 , wherein the amino acid is histidine, and wherein the molar ratio of the histidine to the peptide therapeutic agent in the aqueous composition is less than 2:1.

15. The method of claim 12 , wherein the buffer comprises phosphate, acetate, citrate, or tris(hydroxymethyl)aminomethane.

16. The method of claim 12 , wherein the amino acid is histidine, arginine, or lysine.

17. The method of claim 12 , wherein the aqueous composition or the coating is substantially free of sorbitol.

18. A method of stabilizing a peptide therapeutic agent on or within an array of microneedles, the method comprising incorporating the peptide therapeutic agent and an amino acid on or within the array of microneedles, wherein the peptide therapeutic agent and the amino acid both have a net positive charge, and wherein the peptide therapeutic agent is a parathyroid hormone-related protein analogue represented by formula [Glu 22,25 , Leu 23,28,31 , Aib 29 , Lys 26,30 ]hPTHrP(1-34)NH 2 .

Assignments (5)
SECURITY INTEREST Recorded Dec 14, 2022
From: KINDEVA DRUG DELIVERY L.P.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 062122/0618 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL RECORDED AT R/F 053586/0715 Recorded Dec 12, 2022
From: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT
To: KINDEVA DRUG DELIVERY L.P.
Reel/Frame 062115/0707 →
SECURITY INTEREST Recorded Aug 24, 2020
From: KINDEVA DRUG DELIVERY L.P.
To: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT
Reel/Frame 053586/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2020
From: 3M COMPANY; 3M INNOVATIVE PROPERTIES COMPANY
To: KINDEVA DRUG DELIVERY L.P.
Reel/Frame 052818/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2014
From: ZHANG, YING; FENN, PERCY T.; JOHNSON, PETER R.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 032995/0921 →